Glaukos Corporation Announces Second Quarter 2019 Financial Results

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2019. Key highlights include: Achieved 36% net sales growth to $58.6 million in the second quarter of 2019, compared to $43.2 million in the second quarter of 2018. Reported gross margin of approx

Full Story →

Glaukos Corporation Announces Second Quarter 2019 Financial Results

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2019. Key highlights include: Achieved 36% net sales growth to $58.6 million in the second quarter of 2019, compared to $43.2 million in the second quarter of 2018. Reported gross margin of approx

Full Story →